鲁索利替尼
药代动力学
医学
内科学
毒性
观察研究
人口
临床试验
肿瘤科
药理学
曲线下面积
队列
药品
探索性分析
人口研究
队列研究
分配量
槽浓度
加药
基于生理学的药代动力学模型
体表面积
作者
Jérémie Tachet,Sara C. Meyer,Francesco Grandoni,Emmanuel Haefliger,Monika Nagy-Hulliger,Jörg P. Halter,Jakob Robert Passweg,David Haefliger,Carine Bardinet,Laurent Arthur Decosterd,Monia Guidi,François Girardin
摘要
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring. In total, 221 steady‐state ruxolitinib concentrations from 77 adult patients enrolled across several centers in Switzerland were analyzed. Demographic and clinical data were recorded at each visit. Population pharmacokinetic (popPK) analysis was performed with MonolixSuite® 2024R1 (Lixoft, France). Model‐based simulations were used to predict trough concentration ( C min ) and the area under the concentration–time curve over 24 h (AUC 24 ) for the recommended dosage regimens, as a function of covariates. An exploratory pharmacokinetic/pharmacodynamic analysis was conducted in the overall cohort. Ruxolitinib PK was characterized by a marked between‐subject variability in clearance (45%). Strong cytochrome (CYP) 3A4 or dual CYP2C9/CYP3A4 inhibitors reduced clearance by 39%. At 10 mg twice daily, model‐based simulations showed CYP inhibitors increased median C min and AUC 24 by 2.9‐ and 1.7‐fold, respectively. Still, no significant exposure–efficacy relationship was identified. However, higher ruxolitinib exposure tended to be associated with increased toxicity in the overall population ( C min and AUC 24 , P ≈0.02–0.03). In clinical practice, ruxolitinib exposure shows substantial variability and is strongly affected by strong CYP inhibitors that are frequently co‐administered. Whilst no clear exposure–efficacy relationship was observed, higher exposure was linked to increased toxicity risk, arguing for careful dose adjustment.
科研通智能强力驱动
Strongly Powered by AbleSci AI